Kyowa Kirin Pharmaceutical Research, Inc.
9420 Athena Circle
57 articles with Kyowa Kirin Pharmaceutical Research, Inc.
Kyowa Kirin North America Announces Recipients of Patient Education Grants to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)
Cutaneous Lymphoma Foundation and Lymphoma Research Foundation are Grantees from First Round of Funding Kyowa Kirin Issues a Renewed Call for Submissions, with the Grant Program Extended to 2021
Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. announced the first patient has been dosed in the pivotal Phase 2 study of zandelisib, an oral, once-daily, investigational drug-candidate selective for phosphatidylinositol 3-kinase delta in patients with indolent B-cell non-Hodgkin's lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström's macroglobulinemia in Japan.
Kyowa Kirin Announces Patient Education Grant Program to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, is establishing a general grant program to support the education of African-American patients about cutaneous T-cell lymphomas (CTCL) and address racial disparities in diagnosis, treatment and outcomes. Studie
Kyowa Kirin Names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America
Kyowa Kirin USA Holdings, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, named Ana Bastiani-Posner , MBA, a proven leader with over 20 years of financial experience, as its Executive Vice President, Chief Financial Officer, effective June 29 . Ms. Bastiani-Posner
MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies;
Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program
MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharing
4/10/2020Biopharma companies strengthen their leadership teams and boards with this week's Movers & Shakers.
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Crysvita® for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes
First and only Adenosine A2A receptor antagonist for use in Parkinson’s disease in the U.S.
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. announced plans to submit a supplemental Biologics License Application to the U.S. Food and Drug Administration for Crysvita® for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
First and only Adenosine A2A receptor antagonist for use in Parkinson’s Disease in the U.S.
Nourianz (istradefylline) was given the thumbs-up as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “OFF” episodes.
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
8/31/2018The U.S. Food and Drug Administration has had a busy August. In addition to the number of draft guidance documents the agency issued during the month, the FDA has also been busy approving a number of new treatments for a variety of diseases.
The U.S. Food and Drug Administration today approved Poteligeo injection.
6/4/2018There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
Ultragenyx And Kyowa Hakko Kirin Announce FDA Acceptance And Priority Review Designation Of Burosumab’s Biologics License Application
Syndax Announces Dosing Of First Patient In Pivotal Trial Of Entinostat For The Treatment Of Advanced Or Recurrent Breast Cancer In Japan By Partner Kyowa Hakko Kirin